Sustainability In The Pharma Industry Statistics 2026

Seventy-eight percent of surveyed pharmaceutical executives expect sustainability requirements from customers to keep increasing over the next three years. At the same time, 74% of pharmaceutical manufacturing companies reported environmental compliance pressure from customers and regulators in 2023. The pressure is already translating into measurable changes across wastewater treatment, packaging, and energy use.

Key Takeaways

74% of pharmaceutical manufacturing companies reported experiencing environmental compliance pressure from customers/regulators in 2023
78% of surveyed pharmaceutical executives expect sustainability requirements from customers to increase over the next 3 years (2024 survey result)
14% of pharmaceuticals’ global total final energy use is attributable to manufacturing stages in an LCA-based energy breakdown study for medicines’ supply chains (2021 study finding)
1.7x increase: global demand for green pharmaceutical packaging expected to grow 1.7x by 2030 versus 2023 levels (industry market forecast)
$7.4 billion global environmental services market for healthcare/pharma end use projected by 2030 (forecast figure from industry market research report published 2024)
$20.6 billion forecast global sustainable packaging market in 2030 (market forecast; pharma is a key end-use vertical)
25% lower wastewater chemical oxygen demand (COD) achieved with enzymatic/biological treatment vs conventional treatment in a pharma wastewater treatment pilot study
90% reduction in organics in pharmaceutical wastewater treatment reported in a full-scale activated sludge optimization study (removal efficiency)
98% removal of ethinylestradiol achieved using advanced oxidation (ozonation) in a controlled lab study (pharmaceutical micropollutant)
1.2 billion EUR total estimated EU compliance cost impacts from environmental regulation changes for pharmaceutical manufacturing reported in an EU impact assessment
$120 million in cost savings reported by a major pharma manufacturer after switching to renewable electricity contracts (annual savings figure, company sustainability report data)
€300 million projected capex required for the pharmaceutical sector to upgrade wastewater treatment to meet stricter EU requirements (estimates from policy-related industry analysis)
Directive (EU) 2024/… requires large companies including many pharma firms to report on sustainability under CSRD, covering reporting for financial years starting 1 January 2024
ISO 14001: 370,000+ certificates issued globally as of 2022 (environmental management standard used by pharma for sustainability systems)
GRI Standards are used by 10,000+ organizations globally (most pharma ESG reporters adopt GRI-aligned disclosures for sustainability)

In 2023, environmental compliance pressure intensified, driving major pharma investment in greener packaging, software, and cleaner wastewater.

01 · Category

Industry Trends3 stats

74% of pharmaceutical manufacturing companies reported experiencing environmental compliance pressure from customers/regulators in 2023

78% of surveyed pharmaceutical executives expect sustainability requirements from customers to increase over the next 3 years (2024 survey result)

14% of pharmaceuticals’ global total final energy use is attributable to manufacturing stages in an LCA-based energy breakdown study for medicines’ supply chains (2021 study finding)

Interpretation

Industry Trends Interpretation

In industry trends for sustainability in pharma, 78% of executives expect rising customer sustainability requirements over the next three years, and this pressure is already showing up with 74% of manufacturers reporting environmental compliance demands in 2023.

02 · Category

Market Size8 stats

1.7x increase: global demand for green pharmaceutical packaging expected to grow 1.7x by 2030 versus 2023 levels (industry market forecast)

$7.4 billion global environmental services market for healthcare/pharma end use projected by 2030 (forecast figure from industry market research report published 2024)

$20.6 billion forecast global sustainable packaging market in 2030 (market forecast; pharma is a key end-use vertical)

$4.8 billion projected global market size for pharma serialization and track-and-trace solutions by 2029 (used for compliance and waste reduction via digitization)

$6.2 billion global market for sustainable supply chain management software projected by 2032 (includes sustainability/ESG modules adopted by pharma)

$1.3 billion projected market for pharmaceutical waste management services by 2030 (global forecast; includes hazardous waste and wastewater treatment)

$1.0 billion global market for green chemistry catalysts and reagents in 2023 (enabling pharma process greening)

$5.6 billion market size for environmental compliance software in 2023 (used by pharma for reporting/controls)

Interpretation

Market Size Interpretation

Under the market size category, the pharma sustainability opportunity is scaling fast, with forecasts showing green pharmaceutical packaging demand rising 1.7x by 2030 alongside a $20.6 billion sustainable packaging market and a $1.3 billion projected pharma waste management services market by 2030.

03 · Category

Performance Metrics11 stats

25% lower wastewater chemical oxygen demand (COD) achieved with enzymatic/biological treatment vs conventional treatment in a pharma wastewater treatment pilot study

90% reduction in organics in pharmaceutical wastewater treatment reported in a full-scale activated sludge optimization study (removal efficiency)

98% removal of ethinylestradiol achieved using advanced oxidation (ozonation) in a controlled lab study (pharmaceutical micropollutant)

3.5x improvement in atom economy (from 0.12 to 0.42) in a redesigned API synthesis route reported in a greening-chemistry case study

30% decrease in energy consumption per unit product reported for a pharma facility following installation of industrial heat recovery (measured energy intensity change)

40% reduction in landfill waste volume achieved by pharma packaging redesign and recycling program in a published operational study

50% reduction in water use (m3/ton of product) in a pharma manufacturing water stewardship program reported by a peer-reviewed facility assessment

60% reduction in particulate emissions during API drying reported in a control-technology evaluation study (capture efficiency)

75% increase in biogas yield from anaerobic digestion of pharmaceutical wastewater sludge under optimized co-digestion conditions (percent increase vs baseline)

0.3 kg CO2e per kg API reported as life-cycle climate impact benchmark for a particular synthesis route in a cradle-to-gate LCA paper (scope: production)

95% yield achieved for a green-solvent substitution route in an API process development study (process performance)

Interpretation

Performance Metrics Interpretation

Across performance metrics in pharma sustainability, major improvements are consistently shown by large gains such as 98% removal of ethinylestradiol with advanced oxidation and 75% higher biogas yield from optimized digestion, alongside process efficiencies like a 3.5x atom economy jump and a 30% energy reduction per unit product.

Sustainability In IndustrySustainability In The Medical Industry Statistics

04 · Category

Cost Analysis8 stats

1.2 billion EUR total estimated EU compliance cost impacts from environmental regulation changes for pharmaceutical manufacturing reported in an EU impact assessment

$120 million in cost savings reported by a major pharma manufacturer after switching to renewable electricity contracts (annual savings figure, company sustainability report data)

€300 million projected capex required for the pharmaceutical sector to upgrade wastewater treatment to meet stricter EU requirements (estimates from policy-related industry analysis)

35% average reduction in operating costs for pharma facilities adopting ISO 14001 environmental management systems (meta-analysis across industrial sectors including pharma)

2-5% energy-cost reduction potential per site from optimizing compressed air systems (applied to manufacturing energy savings relevant to pharma)

30-50% reduction in chemical costs reported when switching from conventional to membrane-based wastewater treatment for specific pharmaceutical effluents (range from engineering review)

€2.7 billion total EU funding available under Horizon Europe for climate and environmental research relevant to green pharma manufacturing (call/program budget figure)

>$1.0 billion procurement spend by large pharma groups on ESG data and compliance tooling (aggregate spend estimate from vendor market survey)

Interpretation

Cost Analysis Interpretation

Cost pressures and opportunities are both intensifying, with EU environmental compliance impacts estimated at 1.2 billion EUR while manufacturers report savings such as 120 million EUR from renewable electricity contracts and up to 35% lower operating costs after ISO 14001 adoption.

05 · Category

Regulatory & Reporting5 stats

Directive (EU) 2024/… requires large companies including many pharma firms to report on sustainability under CSRD, covering reporting for financial years starting 1 January 2024

ISO 14001: 370,000+ certificates issued globally as of 2022 (environmental management standard used by pharma for sustainability systems)

GRI Standards are used by 10,000+ organizations globally (most pharma ESG reporters adopt GRI-aligned disclosures for sustainability)

US EPA: 2023 Toxic Release Inventory (TRI) included 22.3 million pounds of on-site releases from pharmaceutical manufacturing NAICS 3254 (reported total by NAICS group)

UK Modern Slavery Act requires large businesses (including many pharma firms) to publish a slavery and human trafficking statement annually; compliance threshold is 36,000 GBP turnover

Interpretation

Regulatory & Reporting Interpretation

Under the Regulatory & Reporting lens, pharma companies face intensifying disclosure expectations as EU CSRD starts covering financial years from 1 January 2024 and is backed by widespread reporting frameworks like GRI used by 10,000+ organizations, while environmental accountability is also measurable through tools such as ISO 14001 with 370,000+ certificates globally and US EPA 2023 TRI data showing 22.3 million pounds of on-site releases from NAICS 3254 pharmaceutical manufacturing.

06 · Category

Emissions & Targets1 stats

53% of manufacturing sites reported as powered by renewable electricity by 2022 in Merck KGaA’s sustainability reporting (renewable electricity share across manufacturing locations)

Interpretation

Emissions & Targets Interpretation

In the Emissions and Targets landscape, Merck KGaA reported that 53% of its manufacturing sites were powered by renewable electricity by 2022, signaling a meaningful shift toward lowering emissions through cleaner energy.

Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA

Priyanka Sharma. (2026, February 13). Sustainability In The Pharma Industry Statistics. Gitnux. https://gitnux.org/sustainability-in-the-pharma-industry-statistics

MLA

Priyanka Sharma. "Sustainability In The Pharma Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sustainability-in-the-pharma-industry-statistics.

Chicago

Priyanka Sharma. 2026. "Sustainability In The Pharma Industry Statistics." Gitnux. https://gitnux.org/sustainability-in-the-pharma-industry-statistics.